{"title":"哪些心力衰竭患者受益于SGLT2抑制剂？","authors":"Joseph Benjamen, Michael Fralick","doi":"10.1056/EVIDccon2400446","DOIUrl":null,"url":null,"abstract":"<p><p>AbstractRandomized controlled trials have demonstrated a reduction in the composite of heart failure events and death from cardiovascular causes with use of SGLT2 inhibitors, regardless of whether a patient has type 2 diabetes mellitus. This evidence led to a class 1A indication for SGLT2i for adults with heart failure. However, recent data demonstrate that the adoption of SGLT2i into practice has been slow. This article describes benefits, risks, pivotal trials, prescribing pearls, and areas of uncertainty related to the use of SGLT2i for adults with heart failure.</p>","PeriodicalId":74256,"journal":{"name":"NEJM evidence","volume":"4 8","pages":"EVIDccon2400446"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Which Patients with Heart Failure Benefit from an SGLT2 Inhibitor?\",\"authors\":\"Joseph Benjamen, Michael Fralick\",\"doi\":\"10.1056/EVIDccon2400446\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>AbstractRandomized controlled trials have demonstrated a reduction in the composite of heart failure events and death from cardiovascular causes with use of SGLT2 inhibitors, regardless of whether a patient has type 2 diabetes mellitus. This evidence led to a class 1A indication for SGLT2i for adults with heart failure. However, recent data demonstrate that the adoption of SGLT2i into practice has been slow. This article describes benefits, risks, pivotal trials, prescribing pearls, and areas of uncertainty related to the use of SGLT2i for adults with heart failure.</p>\",\"PeriodicalId\":74256,\"journal\":{\"name\":\"NEJM evidence\",\"volume\":\"4 8\",\"pages\":\"EVIDccon2400446\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NEJM evidence\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1056/EVIDccon2400446\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NEJM evidence","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1056/EVIDccon2400446","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/22 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Which Patients with Heart Failure Benefit from an SGLT2 Inhibitor?
AbstractRandomized controlled trials have demonstrated a reduction in the composite of heart failure events and death from cardiovascular causes with use of SGLT2 inhibitors, regardless of whether a patient has type 2 diabetes mellitus. This evidence led to a class 1A indication for SGLT2i for adults with heart failure. However, recent data demonstrate that the adoption of SGLT2i into practice has been slow. This article describes benefits, risks, pivotal trials, prescribing pearls, and areas of uncertainty related to the use of SGLT2i for adults with heart failure.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
